Lupin stated that its US-based unit has inked a pact with Exeltis Inc to promote Solosec, a drug used to treat bacterial vaginosis in women.
As part of the tie up, Exeltis will promote Solosec along with its existing line of women's health products.
Solosec is indicated for the treatment of bacterial vaginosis in adult women and trichomoniasis in adults, a common non-viral, curable sexually transmitted infection in the US.
''This partnership will expand the reach of Solosec, allowing more healthcare providers to be aware of its benefits, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis,'' stated Lupin CEO Vinita Gupta.
SEBI Clears 12 IPOs Worth Thousands Of Crores, Including Infra Market, Sify Infinit Spaces & Purple Style Labs
How To Reach Mahalaxmi Racecourse By Metro Aqua Line, Train For Lollapalooza 2026 In Mumbai? Easiest & Fastest Route Inside
Middle East On Boil: Flight Cancellations Plague UAE, Saudi Arabia & Israel As US-Iran Standoff Escalates; Air France, Lufthansa's Operations Hit
ED Attaches Properties Worth ₹16 Crore In Apexa Group Ponzi Fraud Case
(With inputs from PTI)
